Kura Oncology, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
KURA$7.57+4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenue | |||
| Product revenue, net | $2,132 | $— | $— |
| Collaboration revenue | 65,350 | 53,883 | — |
| Total revenue | 67,482 | 53,883 | — |
| Operating Expenses | |||
| Cost of product sales | 57 | — | — |
| Research and development | 251,074 | 169,967 | 115,235 |
| Selling, general and administrative | 119,982 | 77,111 | 50,569 |
| Total operating expenses | 371,113 | 247,078 | 165,804 |
| Loss from operations | (303,631) | (193,195) | (165,804) |
| Other Income (Expense) | |||
| Interest and other income, net | 26,774 | 22,849 | 14,722 |
| Interest expense | (1,512) | (1,619) | (1,549) |
| Total other income, net | 25,262 | 21,230 | 13,173 |
| Loss before income taxes | (278,369) | (171,965) | (152,631) |
| Income tax expense | 297 | 2,018 | — |
| Net Loss | $(278,666) | $(173,983) | $(152,631) |
| Net loss per share, basic and diluted | $(3.18) | $(2.02) | $(2.08) |
| Weighted average number of shares used in computing net loss per share, basic and diluted | 87,676 | 86,161 | 73,229 |
| Comprehensive Loss | |||
| Net loss | $(278,666) | $(173,983) | $(152,631) |
| Other comprehensive income | |||
| Unrealized gain on short-term investments | 260 | 2,035 | 6,761 |
| Comprehensive loss | $(278,406) | $(171,948) | $(145,870) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.